Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2022. Although the request metadata says “2021 Q3,” the filing is for Palatin’s fiscal third quarter of 2022; the comparable periods ended March 31, 2021.
Business context
Palatin is a clinical-stage biopharmaceutical company that also markets Vyleesi (bremelanotide) in the United States for HSDD in premenopausal women. Its development programs include melanocortin-receptor candidates for inflammatory and other diseases, and natriuretic-peptide candidates. Vyleesi is licensed to partners for China and Korea.
Financial performance and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net product revenue, 2022 | $216,097 | $447,719 |
| License and contract revenue, 2022 | — | $250,000 |
| Total revenue, 2022 | $216,097 | $697,719 |
| Total revenue, 2021 | $88,741 | $(363,790) |
| Research and development expense, 2022 | $4.98 million | $13.89 million |
| Selling, general and administrative expense, 2022 | $3.01 million | $10.16 million |
| Net loss, 2022 | $(7.63) million | $(23.43) million |
| Net loss per share, 2022 | $(0.03) | $(0.10) |
- Quarterly net revenue increased from $88,741 to $216,097. Nine-month 2021 net product revenue was negative due to product-sales allowances related to regaining Vyleesi rights; the 2022 nine-month comparison also includes $250,000 of Fosun license revenue.
- Quarterly and nine-month net losses widened from $5.73 million and $19.66 million, respectively. R&D expense increased year over year, primarily from higher spending on melanocortin-receptor programs. SG&A declined, partly due to lower Vyleesi selling costs.
- Operating cash use was $22.20 million for the nine months, versus $14.11 million in 2021. The filing attributes the increase mainly to prior-year cash received under the Vyleesi termination agreement and higher program spending.
- Cash and cash equivalents were $37.72 million at March 31, 2022, down from $60.10 million at June 30, 2021. Current assets were $42.25 million and current liabilities $11.98 million.
- No material conventional borrowing balance is identified; reported financing obligations include operating and finance lease liabilities. Total lease liabilities were approximately $1.27 million. Stockholders’ equity was $28.09 million, down from $49.65 million at June 30, 2021.
Outlook, risks and unusual items
- Management said existing cash was expected to fund current operating plans through at least June 2023, but additional funding will be needed for required clinical trials and potential regulatory submissions. Profitability is uncertain.
- PL9643 entered Phase 3 trials in the fourth quarter of calendar 2021; PL8177 was expected to enter Phase 2 in calendar 2022. Trial outcomes, timing, costs and regulatory approvals remain uncertain.
- Vyleesi supply agreements carry $9.83 million of inventory purchase commitments. The filing says $5.93 million was accrued in current liabilities and $2.995 million in long-term liabilities for estimated losses; the balance sheet reports total other long-term liabilities of $2.955 million, so the long-term figures should be reconciled.
- Risks include product uptake and commercialization, clinical and regulatory execution, dependence on contract manufacturers and collaborators, financing availability, COVID-19-related disruption, and potential impacts of the Russia-Ukraine conflict. Foreign-exchange movements can also affect supply commitments.
- After quarter-end, Palatin completed a private placement for $15 million gross proceeds in Series B and Series C convertible redeemable preferred stock, with warrants. The preferred stock could convert into about 33.33 million common shares at an initial $0.45 conversion price or, during the specified period, be redeemed for cash or notes with a 5% redemption fee. This creates potential dilution or a redemption obligation. Management also planned to seek stockholder approval for a reverse stock split.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2022.
Key facts investors should verify
- Whether Vyleesi sales and net revenue improve, and how sales allowances affect reported revenue.
- Actual cash runway and financing needs against management’s June 2023 estimate, including the preferred-stock conversion or redemption outcome.
- Clinical progress, spending and results for PL9643, PL8177 and other development programs.
- The status and expected cash impact of Vyleesi supply commitments, including the long-term liability figure inconsistency in the filing.
- Potential dilution from preferred-stock conversion, warrants, options and restricted stock units.